Ascelia Pharma AB (publ)
ACE
Rank in Stocks
#29906
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on... Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Share Price
$0.05366575
Last synced: 2026-11-09
Market Cap
$6.56M
Change (1 day)
-4.87%
Change (1 year)
-83.02%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Ascelia Pharma AB (publ) (ACE)
Category
Healthcare
EPS for Ascelia Pharma AB (publ) (ACE)
EPS as of June 2026 TTM: $-0.05
According to Ascelia Pharma AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.05. At the end of 2025 the company had an EPS of $-0.07, an increase over its 2024 EPS of $-0.13.
EPS history for Ascelia Pharma AB (publ) from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.05 | -30.86% |
| 2025 | $-0.07 | -45.90% |
| 2024 | $-0.13 | -58.22% |
| 2023 | $-0.32 | -11.17% |
| 2022 | $-0.36 | -14.33% |
| 2021 | $-0.42 | -7.23% |
| 2020 | $-0.46 | 132.14% |
| 2019 | $-0.20 | 62.25% |
| 2018 | $-0.12 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -32,455.37% |
US
|
|
| $-7.07 | 14,507.44% |
US
|
|
| $-5.29 | 10,829.75% |
AU
|
|
| $12.88 | -26,711.78% |
BE
|
|
| $21.56 | -44,645.45% |
NL
|
Questions about Ascelia Pharma AB (publ)'s earnings per share (EPS)
What is Ascelia Pharma AB (publ)'s earnings per share (EPS)?
Ascelia Pharma AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.05, as of Jun 2026.
What was Ascelia Pharma AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Ascelia Pharma AB (publ)'s earnings per share (EPS) was $-0.07, compared with $-0.13 in 2024.
How has Ascelia Pharma AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Ascelia Pharma AB (publ)'s earnings per share (EPS) was highest in 2025 ($-0.07) and lowest in 2020 ($-0.46).
How does Ascelia Pharma AB (publ)'s earnings per share (EPS) compare with similar companies?
Ascelia Pharma AB (publ)'s earnings per share (EPS) ($-0.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.